首页 | 本学科首页   官方微博 | 高级检索  
检索        

重组人生长激素在肝硬变围手术期应用的临床研究
引用本文:鲁建国,董瑞,宁力,马庆久,褚延魁,王青,乔庆,杜锡林.重组人生长激素在肝硬变围手术期应用的临床研究[J].中国普外基础与临床杂志,2006,13(3):311-313.
作者姓名:鲁建国  董瑞  宁力  马庆久  褚延魁  王青  乔庆  杜锡林
作者单位:第四军医大学唐都医院普外科,西安,710038
摘    要:目的探讨重组人生长激素(rhGH)对肝硬变门静脉高压症患者术后肝功能和营养代谢的影响。方法将2003年2月至2004年1月期间我院收治的48例肝硬变患者随机均分为rhGH组和对照组,2组患者分别于术后第2d给予rhGH或生理盐水,共7d,检测2组患者的白蛋白水平、肝功能及血糖水平。结果rhGH组治疗后第7d起,血浆白蛋白水平明显高于对照组相应时相(P〈0.05);血ALT、AST明显低于对照组相应时相(P〈0.05);2组血糖含量随治疗时间延长逐渐降低,治疗后第14d恢复正常,但2组血糖治疗前、后相应时相比较差异无统计学意义(P〉0.05);2组血浆胆红素水平于治疗前、后相应时相比较差异无统计学意义(P〉0.05)。结论rhGH可促进肝硬变门静脉高压症患者术后蛋白质的合成,纠正低蛋白血症,改善肝功能。

关 键 词:肝硬变  重组人生长激素
文章编号:1007-9424(2006)03-0311-03
收稿时间:2005-09-30
修稿时间:2006-02-21

Study of the Clinical Application of Recombinant Human Growth Hormone During Perioperation Cirrhosis Patients
LU Jian-guo,DONG Rui,NING Li,MA Qing-jiu,CHU Yan-kui,WANG Qing,QIAO Qing,DU Xi-lin.Study of the Clinical Application of Recombinant Human Growth Hormone During Perioperation Cirrhosis Patients[J].Chinese Journal of Bases and Clinics In General Surgery,2006,13(3):311-313.
Authors:LU Jian-guo  DONG Rui  NING Li  MA Qing-jiu  CHU Yan-kui  WANG Qing  QIAO Qing  DU Xi-lin
Abstract:Objective To prospectively study the effects of recombinant human growth hormone (rhGH) on the changes of liver function and nutritional metabolism in postoperative patients with cirrhosis and portal hypertension. Methods Forty-eight cases with liver cirrhosis and portal hypertension who were collected from February 2003 to January 2004 were randomly divided into 2 groups (24 patients in each group). All patients were given the low calorie parenteral nutrition support and exogenous albumen after operations. Patients in the study group received rhGH from the second day after operations and physiological saline was used in the control group instead. The effects were evaluated in terms of protein metabolism, liver function, blood glucose level at different phases before and after the intervene. Death rates of in patients were also recorded in both groups. Results The rising amplitude of albumen in the study group had been significantly larger than that of the control group from the seventh day after intervene (P<0.05). The blood transaminase levels (ALT,AST) in the study group were significantly lower than that of the control group (P<0.05). The blood glucose level of both groups decreased over time and returned to normal on day 14 after intervene, but there was no significant difference for both glucose and plasma bilirubin level between the two groups before and after the intervene (P> 0.05). The rates of death were similar, although the length of stay in the study group was much shorter than that of the control group. Conclusion rhGH may inhibit the catabolism, correct hypoproteinemia, improve liver function for post-operative patients with cirrhosis and portal hypertension, and reduce their length of stay.
Keywords:Liver cirrhosis Recombinant human growth hormone
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号